Response to eculizumab in a teenager with c3 glomerulopathy and thrombotic microangiopathy: A clinic case
PDF (Español)

Keywords

C3 Glomerulopathy
Membranoproliferative glomerulonephritis
Eculizumab
Dense deposit disease
Alternative complement pathway
C3

How to Cite

1.
Ramírez Corredor A, López Villalba ME, Castillo M. Response to eculizumab in a teenager with c3 glomerulopathy and thrombotic microangiopathy: A clinic case. Rev. Colomb. Nefrol. [Internet]. 2024 Mar. 27 [cited 2024 Jul. 15];11(1). Available from: https://revistanefrologia.org/index.php/rcn/article/view/673

Abstract

Background: C3 glomerulopathy is a rare entity, secondary to a dysregulation of complement alternative pathway

Purpose: The purpose of this article is to report the case of a teenager who presented acute glomerulonephritis, initially suspecting membranoproliferative glomerulonephritis and/or poststreptococcal glomerulopathy, with significant compromise of glomerular filtration, low C3 levels, severe arterial hypertension and proteinuria with renal biopsy compatible with C3 glomerulopathy, with a membranoproliferative pattern also suggestive of thrombotic microangiopathy

Case presentation: We report the case of a teenager who was diagnosed with C3 glomerulopathy and thrombotic microangiopathy, without response to initial 8-week management with steroids.

Discussion and conclusions: This is a rare and recently described entity, with evidence of significant compromise in renal function and some patients, progression to renal failure. In the case of this teenager, he received anticomplement therapy with eculizumab with resolution of the diasease, in the follow-up, was achieved without evidence of complications or side effects documented to date.

https://doi.org/10.22265/acnef.11.1.673
PDF (Español)

References

Smith RJ, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019 mzo.;15(3):129-43. https://doi.org/10.1038/s41581-018-0107-2

George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014 ag. 14;371(7):654-66. https://doi.org/10.1056/NEJMra1312353

Palma LM, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol. 2022 sept.;37(9):1967-80. https://doi.org/10.1007/s00467-021-05370-8

Ravindran A, Pereira Palma LM, Fervenza FC, Sethi S. Overlap of C3 Glomerulopathy and Thrombotic Microangiopathy: A Case Series. Kidney Int Rep. 2023 mzo.;8(3):619-27. https://doi.org/10.1016/j.ekir.2022.12.009

Noris M, Remuzzi G. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. Am J Kidney Dis. 2015 ag.;66(2):359-75. https://doi.org/10.1053/j.ajkd.2015.03.040

Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013 dic.;84(6):1079-89. https://doi.org/10.1038/ki.2013.377

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 oct.;100(4):S1-276. https://doi.org/10.1016/j.kint.2021.05.021

Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Update on C3 Glomerulopathy: A Complement-Mediated Disease. Nephron. 2020;144(6):272-80. https://doi.org/10.1159/000507254

Riedl M, Thorner P, Licht C. C3 Glomerulopathy. Pediatr Nephrol. 2017 en.;32(1):43-57. https://doi.org/10.1007/s00467-015-3310-4

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, et al. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Am J Kidney Dis. 2019 ag.;74(2):224-38. https://doi.org/10.1053/j.ajkd.2018.12.046

Hou J, Ren KYM, Haas M. C3 Glomerulopathy: A Review with Emphasis on Ultrastructural Features. Glomerular Dis. 2022 abr. 12;2(3):107-20. https://doi.org/10.1159/000524552

Gale DP, Maxwell PH. C3 glomerulonephritis and CFHR5 nephropathy. Nephrol Dial Transplant. 2013 febr. 1;28(2):282-8. https://doi.org/10.1093/ndt/gfs441

Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, et al. Treating C3 glomerulopathy with eculizumab. BMC Nephrol. 2018 dic.;19(1):7. https://doi.org/10.1186/s12882-017-0802-4

Holle J, Berenberg-Goßler L, Wu K, Beringer O, Kropp F, Müller D, et al. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol. 2018 dic.;33(12):2289-98. https://doi.org/10.1007/s00467-018-4034-z

Oosterveld MJS, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJTH, Van Den Heuvel LP, et al. Eculizumab in Pediatric Dense Deposit Disease. Clin J Am Soc Nephrol. 2015 oct.;10(10):1773-82. https://doi.org/10.2215/CJN.01360215

McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017 jul. 14;66(27):734-7. https://doi.org/10.15585/mmwr.mm6627e1

Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, et al. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis. 2018 jul.;72(1):84-92. https://doi.org/10.1053/j.ajkd.2017.11.019

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, et al. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Am J Kidney Dis. 2019;74(2):224-38. https://doi.org/10.1053/j.ajkd.2018.12.046

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dimensions


PlumX


Downloads

Download data is not yet available.